Geneva, June 20 -- International Clinical Trials Registry received information related to the study (ISRCTN78546774) titled 'Integrating Chinese herbal medicine in advanced lung cancer: a multicenter real-world study using target trial emulation' on June 9.
Study Type: Observational
Study Design:
Multi-center retrospective target trial emulation (Treatment)
Primary Sponsor: Chang Gung Medical Foundation
Condition:
Stage IV non-small cell lung cancer.
Cancer
Intervention:
Chinese herbal medicine, modified according to illness and physicians' clinical experience (at least 28 days of oral Chinese herbal medicine treatment, twice to three times a day). The follow-up duration was set as 10 years after diagnosis or to the date of 31/12...